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	 A	 simple	and	precise	 liquid	 chromatographic	method	has	 been	 developed	and	validated	 for
the	determination	of	either	sitagliptin	(STG),	vildagliptin	(VLG)	or	saxagliptin	HCL	(SXG)	and
metformin	HCL	(MET)	 in	the	presence	of	metformin	degradation	product,	1‐cyanoguanidine
(CGN).	Chromatographic	separation	was	achieved	on	a	Symmetry®	cyanide	column	(150	mm
×	4.6	mm,	5	μm).	Isocratic	elution	using	a	mobile	phase	of	potassium	dihydrogen	phosphate
buffer	(pH	=	4.6)	‐	acetonitrile	(30:70,	v:v)	at	a	flow	rate	of	1	mL/min	with	UV	detection	at	210
nm	was	performed.	The	LC	method	was	used	for	the	simultaneous	determination	of	STG,	VLG,
SXG	 and	MET	 in	 the	 ranges	 of	 5‐200,	 5‐200,	 0.5‐80.0	 and	 20‐800	 μg/mL,	 respectively.	 The
results	were	 statistically	 compared	with	 the	 reference	method	 for	each	drug	using	one‐way
analysis	of	variance	(ANOVA).	The	method	developed	was	satisfactorily	applied	to	the	analysis
of	 the	 pharmaceutical	 formulations	 and	 proved	 to	 be	 specific	 and	 accurate	 for	 the	 quality
control	of	the	cited	drugs	in	pharmaceutical	dosage	forms.	
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1.	Introduction	
	
Sitagliptin	 (Figure	 1a),	 vildagliptin,	 (Figure	 1b),	 and	
saxagliptin	 (Figure	 1c)	 are	 oral	 hypoglycemic	 drugs	 of	 the	
dipeptidyl	 peptidase‐4	 (DPP‐4)	 inhibitors	 class.	 DPP‐4	
inhibitors	 represent	 a	 new	 therapeutic	 approach	 to	 the	
treatment	 of	 type‐2	 diabetes	 that	 functions	 to	 stimulate	
glucose‐dependent	insulin	release	and	reduce	glucagons	levels.	
This	is	done	through	inhibition	of	the	inactivation	of	 incretins,	
particularly	 glucagon‐like	 peptide‐1	 (GLP‐1)	 and	 gastric	
inhibitory	polypeptide	(GIP)	[1].	
Few	methods	have	been	described	for	the	determination	of	
STG	 in	 pharmaceutical	 preparations	 or	 biological	 fluids	
including	 spectrophotometry	 [2]	 and	 high	 performance	 liquid	
chromatography	 (HPLC)	 [1,3].	 A	 liquid	 chromatographic	 (LC)	
method	was	 reported	 for	 the	determination	of	STG	 in	 ternary	
mixture	with	MET	and	sitagliptin	degradation	product	[4].	For	
VDG,	 literature	 survey	 reveals	 that	 only	 one	 spectroscopic	
method	 and	 one	 LC	 method	 were	 reported	 for	 its	
determination	[5,6].	SXG	is	recently	approved	for	the	treatment	
of	 type‐2	 diabetes	mellitus	 [7].	 Literature	 survey	 reveals	 that	
only	 one	 LC‐MS/MS	 [8]	 and	 one	 spectrophotometric	 method	
have	been	reported	for	its	determination	[9].	
Metformin	 (Figure	 1d),	 is	 a	 biguanide	 hypoglycemic	 drug	
that	 is	 regarded	 as	 the	main	 compound	 in	mixed	 therapies	 of	
oral	 hypoglycemics.	 Literature	 survey	 reveals	 some	 methods	
for	the	determination	of	MET	in	mixtures	including	LC/MS/MS	
[10]	 and	 HPLC	 [11‐14].	 1‐Cyanoganidine	 (CGN)	 is	 a	 potential	
impurity	of	metformin	hydrochloride,	which	is	reported	in	USP	
and	 BP	 (Figure	 1e)	 [15,16].	 Only	 one	 LC	 method	 has	 been	
reported	for	the	determination	of	MET	in	the	presence	of	CGN	
[16].	
	
(a)	
	
(b)	
 
(c) 
 
 
(d) 
	
	
(e)	
Figure	 1.	 Chemical	 structures	 of	 the	 drugs;	 (a)	 Sitagliptin,	 [(2R)‐1‐(2,4,5‐
trifluorophenyl)‐4‐oxo‐4‐[3‐(trifluoromethyl)‐5,6‐dihydro	 [1,2,4]	 triazolo	
[4,3‐a]	 pyrazin‐7(8H)‐yl]	 butan‐2‐amine];	 (b)	 Vildagliptin,	 S‐1‐[N‐(3‐
hydroxy‐1‐adamantyl)	 glycyl]	 pyrrolidine‐2‐carbonitrile;	 (c)	 Saxagliptin,	
(1S,3S,5S)‐2‐[(2S)‐2‐amino‐2‐(3‐hydroxy‐1‐adamantyl)acetyl]‐2‐azabicyclo[
3.1.0]	 hexane‐3‐carbonitrile;	 (d)	 Metformin,	 N,N‐dimethylimidodicarbon	
imidic	diamide	;	(e)	Cyanoguanidine.
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The	 aim	of	 the	present	work	was	 to	develop	 and	 validate	
one	 simple	 reversed	 phase	 liquid	 chromatographic	 (RP‐LC)	
method	 that	 could	 be	 applied	 for	 the	 simultaneous	
determination	 of	 each	 of	 the	 three	 commonly	 used	 Gliptins;	
STG,	VDG	and	SXG	and	MET	in	their	ternary	mixture	with	MET	
degradation	product,	CGN	(stability	indicating	assay	for	MET).		
	
2.	Experimental	
	
2.1.	Instrumentation	
	
The	HPLC	system	consisted	of	a	Shimadzu	LC‐20	AT	Liquid	
Chromatograph	 (Japan)	 using	 a	 Symmetry®	 cyanide	 column	
(150	mm	×	4.6	mm,	5	μm)	(Ireland).	The	system	was	equipped	
with	 a	 UV‐visible	 detector	 (SPD‐20A,	 Japan)	 and	 an	 auto	
sampler	 (SIL‐20A,	 Shimadzu,	 Japan).	An	Elma	S100	ultrasonic	
processor	 model	 KBK	 4200	 (Germany)	 was	 used	 for	 the	
degassing	of	the	mobile	phases.	
	
2.2.	Reagents	and	reference	samples	
	
Pharmaceutical	 grade	 STG	 monohydrate,	 certified	 to	
contain	 99.80%,	 Janumet®	 tablets	 nominally	 containing	 64.25	
mg	 of	 STG	 and	 1000	 mg	 of	 MET	 per	 tablet	 were	 all	 kindly	
supplied	 from	 Merck	 Sharp	 and	 Dohme	 Co.	 (Cairo,	 Egypt).	
Pharmaceutical	 grade	 VDG,	 certified	 to	 contain	 99.70%	 and	
Eucreas®	tablets	nominally	containing	50	mg	VDG	and	500	mg	
of	 MET	 per	 tablet	 were	 kindly	 supplied	 from	 Novartis	
Europharm	 Limited	 Company	 (London,	 U.K.).	 Pharmaceutical	
grade	SXG,	certified	to	contain	99.85%	and	Kombiglyze®	tablets	
nominally	 containing	5.58	mg	of	 SXG	and	500	mg	of	MET	per	
tablet	 were	 kindly	 supplied	 by	 Bristol‐Myers	 Squibb/Astra	
Zeneca	 EEIG	 (United	 Kingdom).	 Pharmaceutical	 grade	 MET,	
certified	 to	 contain	 99.79%	was	 kindly	 supplied	 by	 Chemical	
Industries	 Development	 (CID)	 Co.	 (Giza,	 Egypt).	 CGN	 was	
brought	 from	 Fluka	 (Steinheim,	 Germany).	 Methanol	
(HiPerSolv	for	HPLC),	acetonitrile	(HiPerSolv)	were	purchased	
from	 Fisher	 Scientific	 (Loughborough,	 Leicestershire,	 UK).	
Potassium	 dihydrogen	 phosphate	 and	 orthophosphric	 acid	
(85%)	were	obtained	from	VWR	Chemicals	(Pool,	England).	Bi‐
distilled	 water	 was	 produced	 in‐house	 (Aquatron	Water	 Still,	
A4000D,	 UK).	 Membrane	 filters	 0.45	 µm	 from	 Teknokroma	
(Barcelona,	Spain)	were	used.	All	other	chemicals	and	reagents	
used	 were	 of	 analytical	 grade	 unless	 indicated	 otherwise.	
Standard	 stock	 solutions	 of	 each	 drug	 (1	 mg/mL)	 were	
prepared	by	dissolving	100	mg	of	the	drug	in	methanol	in	a	100	
mL	 volumetric	 flask	 and	 then	 completed	 to	 volume	 with	
methanol.	 Then	 required	 concentrations	 were	 prepared	 by	
serial	dilutions	with	methanol	of	these	stock	solutions.	
	
2.3.	Chromatographic	conditions	
	
Chromatographic	separation	was	achieved	on	a	Symmetry®	
Cyanide	 column	 (150	mm	 ×	 4.6	mm,	 5	 μm).	 Isocratic	 elution	
using	 a	 mobile	 phase	 consisting	 of	 potassium	 dihydrogen	
phosphate	buffer	(pH	=	4.6)	‐	acetonitrile	(30:70,	v:v)	with	UV	
detection	 at	 210	 nm	was	 performed.	 The	 buffer	 solution	was	
filtered	through	0.45	µm	membrane	filter	and	degassed	for	30	
min	 in	 an	ultrasonic	 bath	prior	 to	use.	 The	mobile	 phase	was	
pumped	 through	 the	 column	 at	 a	 flow	 rate	 of	 1	 mL/min.	
Analyses	 were	 performed	 at	 ambient	 temperature	 and	 the	
injection	volume	was	25	µL.	
	
2.4.	Samples’	preparation	
	
Twenty	 tablets	 of	 each	 pharmaceutical	 preparation	 were	
weighed.	An	accurately	weighed	amount	of	the	finely	powdered	
Janumet®,	 Eucreas®	 and	 Kombiglyze®	 tablets	 equivalent	 to	
(64.25	mg	of	STG	and	1000	mg	of	MET),	(equivalent	to	100	mg	
of	VDG	and	1000	mg	of	MET)	and	 (equivalent	 to	11.16	mg	of	
SXG	and	1000	mg	of	MET)	 respectively	were	made	up	 to	100	
mL	 with	 methanol.	 The	 solutions	 were	 sonicated	 for	 15	 min	
and	 filtered	 followed	 by	 serial	 dilution	 to	 the	 required	
concentrations	for	each	experiment.	
	
2.5.	Procedure	
	
2.5.1.	Linearity	and	repeatability	
	
Accurately	 measured	 aliquots	 of	 working	 standard	
solutions	equivalent	 to	50‐2000	µg	STG,	50‐2000	µg	VLG,	5.0‐
800	 µg	 SXG	 and	 0.2‐8.0	mg	MET	were	 separately	 transferred	
into	four	series	of	10	mL	volumetric	flasks	and	then	completed	
to	 volume	with	methanol.	A	volume	of	25	µL	of	 each	solution	
was	 injected	 into	 the	 chromatograph.	 The	 chromatographic	
conditions	mentioned	in	Section	2.3	including	the	mobile	phase	
at	 a	 flow	 rate	 1	 mL/min,	 detection	 at	 210	 nm	 and	 run	 time	
program	for	10	min	were	adjusted.	The	calibration	curves	were	
obtained	 by	 plotting	 area	 under	 the	 peaks	 (AUP)	 against	
concentrations	 (C).	 The	 repeatability	 of	 the	 method	 was	
assessed	by	analyzing	a	mixture	containing	32.1	μg/mL	of	STG,	
150	μg/mL	of	CGN	and	500	μg/mL	of	MET	(n	=	6).	The	precision	
(%	 R.S.D.)	 was	 calculated	 (Table	 1)	 and	 analyzing	 a	 mixture	
containing	50	μg/mL	of	VDG,	150	μg/mL	of	CGN	and	500	μg/mL	
of	MET	(n	=	6).	The	precision	(%R.S.D.)	was	calculated	(Table	
2).	And	analyzing	a	mixture	containing	5.6	μg/mL	of	SXG,	150	
μg/mL	 of	 CGN	 and	 500	 µg/mL	 of	MET	 (n	=	 6).	 The	 precision	
(%R.S.D.)	was	calculated	(Table	3).	
	
Table	 1.	 System	 suitability	 tests	 of	 the	 proposed	 LC	 method	 for	 the	
simultaneous	 determination	 of	 sitagliptin,	 metformin	 and	 metformin	
degradation	product.	
Item MET	degradation	product	 STG MET
N	 4096	 1984	 1296	
R 4.8 4.1	 4.1
T	 1.01	 1.00		 1.05	
%R.S.D.	of	6	injections 	
Peak area 0.62 0.23 0.54
Retention time 0.82 0.19 0.33
*	 N:	 Number	 of	 theoretical	 plates,	 R:	 Peak	 resolution	 factor,	 T:	 Ttailing	 of	
chromatographic	 peak,	 and	 repeatability	 as	 percent	 relative	 standard	
deviation	 %R.S.D.	 of	 peak	 area	 for	 six	 injections	 and	 reproducibility	 of	
retention	as	%R.S.D.	of	retention	time.	
	
Table	 2.	 System	 suitability	 tests	 of	 the	 proposed	 LC	 method	 for	 the	
simultaneous	 determination	 of	 vildagliptin,	 metformin	 and	 metformin	
degradation	product.	
Item MET	degradation	product	 VLG MET
N	 4096	 2175	 1296	
R	 6.7	 2.5	 2.5	
T	 1.00	 1.02		 1.05	
%R.S.D.	of	6	injections	 	 	 	
Peak area 0.55 0.72 0.44
Retention time 0.49 0.11 0.25
*	 N:	 Number	 of	 theoretical	 plates,	 R:	 Peak	 resolution	 factor,	 T:	 Tailing	 of	
chromatographic	 peak,	 and	 repeatability	 as	 %R.S.D.	 of	 peak	 area	 for	 six	
injections	and	reproducibility	of	retention	as	%R.S.D.	of	retention	time.	
	
Table	 3.	 System	 suitability	 tests	 of	 the	 proposed	 LC	 method	 for	 the	
simultaneous	 determination	 of	 saxagliptin,	 metformin	 and	 metformin	
degradation	product.	
Item MET	degradation	product	 SXG MET
N	 4096	 2704	 1296	
R	 5.3	 3.2	 3.2	
T 1.00 1.04 1.05
%R.S.D.	of 6 injections 	
Peak area 0.48 0.51 0.88
Retention	time	 0.76	 0.27	 0.38	
*	 N:	 Number	 of	 theoretical	 plates,	 R:	 Peak	 resolution	 factor,	 T:	 Tailing	 of	
chromatographic	 peak,	 and	 repeatability	 as	 %R.S.D.	 of	 peak	 area	 for	 six	
injections	and	reproducibility	of	retention	as	%R.S.D.	of	retention	time.	
	
2.5.2.	Assay	of	drugs	in	laboratory	prepared	mixtures	and	in	
pharmaceutical	dosage	forms	
	
The	 procedure	 mentioned	 in	 Section	 2.5.1	 was	 repeated	
using	three	sets	of	laboratory	prepared	mixtures	equivalent	to	
either	 13‐48	μg/mL	 STG,	 20‐75	 μg/mL	VLG	 or	 2.0‐8.5	 μg/mL	
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SXG	 and	 200‐750	 μg/mL	 MET.	 For	 the	 determination	 of	 the	
examined	 drugs	 in	 tablets,	 the	 sample	 solutions	 prepared	
under	 Section	 2.4	 were	 serially	 diluted	 to	 prepare	 solutions	
equivalent	 to	 6.5‐32.0	 and	 100‐500	 μg/mL	 of	 STG	 and	 MET,	
respectively;	 and	 equivalent	 to	 10‐50	 and	 100‐500	 μg/mL	 of	
VLD	and	MET,	respectively;	and	equivalent	to	1.0‐5.5	and	100‐
500	μg/mL	of	SXG	and	MET,	respectively;	and	then	injected	in	
triplicates.	 The	 concentrations	 of	 the	 examined	 drugs	 were	
calculated	by	the	corresponding	calibration	equations.	
	
3.	Results	and	discussion	
	
HPLC	greatly	 reduces	 the	analysis	 time	and	allows	 for	 the	
determination	 of	 many	 individual	 components	 in	 a	 mixture	
using	 one	 single	 procedure	 [17].	 No	 previous	 method	 was	
reported	for	the	LC	determination	of	either	STG,	VDG	or	SXG	in	
their	 ternary	 mixture	 with	 MET	 and	 CGN.	 CGN	 is	 a	 known	
impurity	with	a	 limit	of	not	more	 than	0.02%,	 it	 is	 also	called	
dicyandiamide,	 is	 the	dimer	 of	 cyanamide.	 Efficient	 control	 of	
these	unwanted	compounds	in	a	formulation	is	necessary	[15].	
	
3.1.	Method	development	
	
Different	 chromatographic	 systems	 including	 different	 C18	
columns	 and	 different	 mobile	 phases	 at	 different	 pH	 values	
were	 attempted.	 Unfortunately,	 simultaneous	 elution	 of	 the	
ternary	 mixtures	 at	 reasonable	 time	 could	 not	 be	 achieved.	
Recently,	cyano	columns	have	been	used	for	the	separation	and	
quantitation	of	drugs	[18‐21].	Using	a	mobile	phase	of	acidic	pH	
value,	 C18	 column	 was	 consequently	 replaced	 with	 a	 cyano	
column	 in	 order	 to	 separate	 mixture	 components.	 For	 the	
cyano‐bonded	 phase	 column,	 the	 weak	 polar	 cyano	 groups,	
together	 with	 the	 short	 hydrocarbon	 chains	 allow	 a	 mixed	
mechanism	 of	 separation	 [22],	 and	 hence	 give	 reasonable	
retention	 times	 for	 the	 three	 components	under	 investigation	
in	 every	mixture	 when	 operating	 under	 optimum	 conditions.	
Isocratic	 elution	 based	 on	 potassium	 dihydrogen	 phosphate	
buffer	 (pH	 =	 4.6)	 ‐	 acetonitrile	 (30:70,	 v:v)	 was	 applied.	
Minimum	 retention	 times	 were	 obtained	 at	 a	 flow	 rate	 1	
mL/min.	The	UV	detector	was	operated	at	210	nm	where	good	
detector	 sensitivity	 was	 achieved	 for	 all	 the	 examined	 drugs.	
The	retention	times	were	6.0,	7.1,	6.5,	9.1	and	4.1	min	for	STG,	
VLD,	SXG,	MET	and	CGN,	respectively;	as	presented	in	Figure	2‐
7.		
	
	
	
Figure	 2.	 A	 typical	 LC	 chromatogram	 of	 25	 µL	 injector	 of	 the	 synthetic	
ternary	mixture,	 (a)	metformin	 hydrochloride	 (500	 μg/mL),	 (b)	 sitagliptin	
(32.1	μg/mL)	and	(c)	cyanoguanidine	(150	μg/mL).	
	
3.2.	System	suitability	tests	
	
According	 to	 United	 States	 pharmacopeia	 (USP)	 [23],	
system	 suitability	 tests	 are	 an	 integral	 part	 of	 liquid	
chromatographic	 methods	 in	 the	 course	 of	 optimizing	 the	
conditions	of	the	proposed	method.	In	the	proposed	LC	method,	
system	 suitability	 tests	 are	 used	 to	 verify	 that	 resolution	 and	
reproducibility	 were	 adequate	 for	 analysis	 performed.	
Different	parameters	affecting	the	chromatographic	separation	
were	studied.	The	parameters	of	this	test	are	column	efficiency	
(number	of	theoretical	plates),	tailing	of	chromatographic	peak,	
peak	 resolution	 factor,	 and	 repeatability	 as	 %R.S.D.	 of	 peak	
areas	 for	 six	 injections	 and	 reproducibility	 of	 retention	 times.	
The	results	of	these	tests	are	listed	in	Tables	1‐3.	
	
	
	
Figure	 3. A	 typical	 LC	 chromatogram	 of	 25	 µL	 injector	 of	 the	 synthetic	
ternary	mixture,	(a)	metformin	hydrochloride	(500	μg/mL),	 (b)	vildagliptin	
(50	μg/mL)	and	(c)	cyanoguanidine	(150	μg/mL).	
	
	
	
	
Figure	 4. A	 typical	 LC	 chromatogram	 of	 25	 µL	 injector	 of	 the	 synthetic	
ternary	mixture,	 (a)	metformin	hydrochloride	 (500	μg/mL),	 (b)	 saxagliptin	
hydrochloride	(5.6	μg/mL)	and	(c)	cyanoguanidine	(150	μg/mL).	
	
	
	
	
Figure	5.	A	typical	LC	chromatogram	of	25	µL	 injector	of	 Janumet®	sample	
solution,	(a)	metformin	hydrochloride	(500	μg/mL)	and	(b)	sitagliptin	(32.1	
μg/mL).	
	
3.3.	Method	validation	
	
3.3.1.	Linearity	
	
Linearity	was	studied	for	STG,	VDG,	SXG	and	MET.	A	linear	
relationship	 between	 area	 under	 the	 peak	 (AUP)	 and	
component	 concentration	 (C)	 was	 obtained.	 The	 regression	
equations	were	also	computed.	The	linearity	of	the	calibration	
curves	 were	 validated	 by	 the	 high	 value	 of	 correlation	
coefficients.	 The	 analytical	 data	 of	 the	 calibration	 curves	
including	 standard	 deviations	 for	 the	 slope	 and	 intercept	 (Sb,	
Sa)	are	summarized	in	Tables	4	and	5.	
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Table	4.	Results	obtained	by	LC	method	for	the	determination	of	metformin	in	binary	mixture	with	sitagliptin	or	vildagliptin	or	saxagliptin.	
Item	*	 Metformin	
Retention	time	 9.1
Wavelength	of	detection,	nm	 210
Range	of	linearity,	μg/mL	 20‐800
Regression	equation		 Area ×	10‐6 = 0.0630 Cμg/mL	+ 0.4827
Regression	coefficient	(r2)	 0.9998	
LOD,	μg/mL	 12.26	
LOQ,	μg/mL	 19.7
Sb	 1.6×10‐3	
Sa	 1.4×10‐1	
Confidence	limit	of	the	slope	 0.0630±0.09×10‐1
Confidence	limit	of	the	intercept	 0.4827±0.77×10‐3
Standard	error	of	the	estimation	 0.22
Intraday	%R.S.D.	 0.29‐0.67
Interday	%R.S.D.	 0.13‐1.1
Drug	in	laboratory	mixture		 100.29±1.65	with	STG	
100.57±0.90	with	VLG	
100.23±0.91	with	SXG
Drug	in	dosage	form	 99.71±1.68	(Janumet®)	
99.95±1.20	(Eucreas®)		
100.14±1.19	(Kombiglyze®)	
Drug	added	 100.26±1.48	(Janumet®)		
99.99±1.01	(Eucreas®)		
99.73±1.24	(Kombiglyze®)
*	LOD:	Limit	of	detection,	LOQ:	Limit	of	quantification,	%R.S.D.:	Percent	relative	standard	deviation.	
	
	
Table	5.	Results	obtained	by	LC	method	for	the	determination	of	sitagliptin,	vildagliptin	and	saxagliptin.	
Item	 Sitagliptin	 Vildagliptin Saxagliptin	
Retention	time	 6.0	 7.1	 6.5	
Wavelength	of	detection,	nm	 210	 210	 210		
Range	of	linearity,	μg/mL	 5‐200	 5‐200	 0.5‐80		
Regression	equation		 Area×10‐5	=	0.1013	Cμg/mL+ 0.0736 Area×10‐5 = 0.1126 Cμg/mL	+ 0.4040 Area×10‐5	=	0.1495	Cμg/mL	+ 0.0114
Regression	coefficient	(r2)	 0.9998	 0.9996 0.9987	
LOD,	μg/mL	 1.48	 0.53 0.10	
LOQ,	μg/mL	 4.94	 1.78 0.42	
Sb	 1.16×10‐4	 1.6×10‐4 1.8×10‐4	
Sa	 0.17	 0.22 0.25	
Confidence	limit	of	the	slope	 0.1013±0.02		 0.1126±0.02 0.1495±0.04		
Confidence	limit	of	the	intercept	 0.0736±0.09×10‐4	 0.4040±0.65×10‐4	 0.0114±0.02×10‐4	
Standard	error	of	the	estimation	 0.19	 0.27	 0.31	
Intraday	%R.S.D.	 0.29‐0.58	 0.21‐0.42 0.43‐0.68	
Interday	%R.S.D.	 0.31‐1.14	 0.23‐0.92	 0.56‐1.31	
Drug	in	laboratory	mixture		 100.32±1.44	 100.17±1.41 100.01±1.51	
Drug	in	dosage	form	 100.13±1.15	 99.95±1.60 99.85±1.68	
Drug	added	 100.52±1.21	 100.24±1.65 99.53±1.46	
*	LOD:	Limit	of	detection,	LOQ:	Limit	of	quantification,	%R.S.D.:	Percent	relative	standard	deviation.	
	 	
	
	
	
Figure	6.	A	 typical	LC	chromatogram	of	25	µL	 injector	of	Eucreas®	sample	
solution,	(a)	metformin	hydrochloride	(500	μg/mL)	and	(b)	vildagliptin	(50	
μg/mL).	
	
	
3.3.2.	Accuracy	
	
Accuracy	of	the	results	was	calculated	by	%	recovery	of	five	
different	solutions	of	the	laboratory	prepared	mixtures	of	STG,	
VLD	and	SXG	 in	 their	 ternary	mixture	with	MET	and	CGN	and	
also	 by	 standard	 addition	 technique	 for	 Janumet®,	 Eucreas®	
and	 Kombiglyze®	 tablets.	 The	 results	 obtained	 including	 the	
mean	of	 the	 recovery	and	standard	deviation	are	displayed	 in	
Tables	4	and	5.	
3.3.3.	Precision	
	
The	 repeatability	 of	 the	 method	 was	 assessed	 by	 six	
determinations	 for	 each	 of	 the	 three	 concentrations	 of	 the	
laboratory	 prepared	 mixture	 of	 STG	 (25.7,	 32.1,	 and	 38.5	
μg/mL)	with	MET	 (400,	 500,	 and	600	 μg/mL)	 and	CGN	 (120,	
150,	 and	 180	 μg/mL)	 representing	 80,	 100	 and	 120%,	
respectively,	 and	 three	 concentrations	 of	 the	 laboratory	
prepared	 mixture	 of	 VLG	 (40,	 50,	 and	 60	 μg/mL)	 with	 MET	
(400,	 500,	 and	 600	 μg/mL)	 and	 CGN	 (120,	 150,	 and	 180	
μg/mL)	 representing	 80,	 100,	 and	 120%,	 respectively,	 and	
three	concentrations	of	the	laboratory	prepared	mixture	of	SXG	
(4.5,	5.6,	and	6.7	μg/mL)	with	MET	(400,	500,	and	600	μg/mL)	
and	 CGN	 (120,	 150,	 and	 180	 μg/mL)	 representing	 80,	 100,	
120%,	respectively.	The	repeatability	of	sample	application	and	
measurement	 of	 peak	 area	 for	 active	 compound	 were	
expressed	 in	 terms	 of	 percentage	 relative	 standard	 deviation	
(%R.S.D.)	 and	 found	 to	 be	 less	 than	 1%	 in	 the	 three	
concentrations.	Results	 for	 the	determination	of	precision	 are	
displayed	in	Tables	1‐5.	
	
3.3.4.	Specificity	
	
Specificity	is	the	ability	of	the	analytical	method	to	measure	the	
analyte	 response	 in	 the	 presence	 of	 interferences	 including	
degradation	products	and	related	substances.		
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Table	6.	Statistical	comparison	between	the	results	of	the	proposed	LC	method	and	the	reference	method	for	the	determination	of	metformin.	
Statistical	term	a	 Reference	method	b	 Proposed	method		
Mean 100.4 100.36
S.D.	 0.28 1.15
S.E.	 0.13 0.51	
%R.S.D.	 0.28	 1.15	
n	 5	 5	
V	 0.08	 1.32	
t	(2.306)	c ‐	 0.08
a	S.D.:	Standard	deviation,	S.E.:	Standard	error,	%R.S.D.:	Relative	standard	deviation,	n:	Number	of	samples,	V:	Variance.	
b	Reference	method	for	the	spectrophotometric	determination	of	metformin	in	the	Indian	Pharmacopeia	[24].	
c	Figures	in	parentheses	are	the	theoretical	t	value	at	(p	=	0.05).	No	significant	difference	between	groups	by	using	one	way	ANOVA	with	F	=	0.01	and	p	=	0.94.			
	 	
	
Table	7.	Statistical	comparison	between	the	results	of	the	LC	method	and	the	reference	methods	for	the	determination	of	sitagliptin,	vildagliptin	and	saxagliptin.	
Statistical	
Term	
Reference	
Method	for	sitagliptin	b	
HPLC	method		 Reference	
Method	for	vildagliptin	c	
HPLC	method		 Reference	
Method	for	saxagliptin	d	
	HPLC	method		
Mean 100.50	 100.32	 100.01 100.17 100.20 100.01
S.D.	 1.39	 1.44	 0.99 1.41 1.10 1.51
S.E.	 0.62	 0.64	 0.44 0.63 0.49 0.68
%R.S.D.	 1.38	 1.44	 0.99	 1.41	 1.1	 1.51	
n	 5	 5	 5 5 5 5	
V	 1.93	 2.1	 0.98	 1.98	 1.21	 2.28	
t	(2.306)	a 	 0.20	 	 0.21	 	 0.23	
a	Figure	in	parentheses	are	the	theoretical	t	value	at	(p	=	0.05).	
b	Reference	method:	aliquots	of	standard	solutions	in	distilled	water	containing	2‐10	μg/mL	STG	were	measured	using	methanol	as	a	blank	[5].	No	significant	
difference	between	groups	of	sitagliptin	by	using	one	way	ANOVA	with	F	=	0.04	and	p	=	0.85.	
c	 Reference	method:	 aliquots	 of	 standard	 solutions	 in	 distilled	water	 containing	 5‐25	 μg/mL	VDG	were	measured	using	water	 as	 a	 blank	 [5].	 No	 significant	
difference	between	groups	of	vildagliptin	by	using	one	way	ANOVA	with	F	=	0.04	and	p	=	0.84.	
d	Reference	method:	aliquots	of	standard	solutions	in	distilled	water	containing	5‐40	μg/mL	SXG	were	measured	using	methanol	as	a	blank	[9].	No	significant	
difference	between	groups	of	saxagliptin	by	using	one	way	ANOVA	with	F	=	0.05	and	p	=	0.83.	
	
	
	
	
Figure	 7.	 A	 typical	 LC	 chromatogram	 of	 25	 µL	 injector	 of	 Kombiglyze®
sample	 solution,	 (a)	 metformin	 hydrochloride	 (500	 μg/mL)	 and	 (b)	
saxagliptin	hydrochloride	(5.6	μg/mL).	
	
	
In	 the	present	work,	 specificity	was	 checked	 by	 analyzing	
STG	with	MET,	VDG	with	MET	and	SXG	with	MET	in	laboratory	
prepared	mixtures	with	 CGN.	 Good	 resolution	 and	 absence	 of	
interference	between	drugs	being	analyzed	are	shown	in	Figure	
2‐7.	 Besides,	 the	 chromatograms	 of	 the	 pharmaceutical	
formulation	 samples	were	 checked	 for	 the	 appearance	 of	 any	
extra	peaks.	No	chromatographic	 interference	 from	any	of	 the	
excipients	 was	 found	 at	 the	 retention	 times	 of	 the	 examined	
drugs	(Figure	5‐7).	In	addition,	the	chromatograms	of	the	drugs	
in	 the	 samples’	 solutions	 were	 found	 identical	 to	 the	
chromatograms	 received	 by	 the	 standard	 solutions	 at	 the	
wavelengths	applied.	Moreover,	good	results	were	obtained	for	
the	determination	of	 the	cited	drugs	 in	 the	 two	dosage	 forms,	
Tables	 4	 and	 5.	 These	 results	 confirm	 the	 absence	 of	
interference	 from	 other	 materials	 in	 the	 pharmaceutical	
formulations	 and	 therefore	 confirm	 the	 specificity	 of	 the	 two	
proposed	methods.	
	
3.3.5.	Robustness	
	
The	 most	 important	 parameter	 to	 be	 studied	 was	 the	
resolution	factor	between	the	two	peaks	of	STG	and	MET,	VLG	
and	 MET	 and	 also	 between	 the	 two	 peaks	 of	 SXG	 and	 MET.	
Besides,	 any	 interference	 from	 the	 peak	 of	 CGN	was	 checked	
visually.	The	flow	rate	of	the	mobile	phase	was	changed	from	1	
mL/min	 to	 0.8	 mL/min	 and	 1.2	 mL/min,	 where	 resolution	
factors	 obtained	were	 (4.1,	 2.5,	 and	3.2),	 (4.2,	 2.45,	 and	3.11)	
and	(4.15,	2.6,	and	3.2),	respectively.	The	organic	strength	was	
changed	by	%±2	where	resolution	 factors	obtained	were	(4.1,	
2.5,	 and	 3.2),	 (4.25,	 2.5,	 and	 3.28)	 and	 (4.12,	 2.6,	 and	 3.35),	
respectively.		
Finally,	 a	 value	 of	 pH	 of	 the	 phosphate	 buffer	was	 varied	
from	4.6	to	4.5	and	4.7,	where	resolution	factors	obtained	were	
(4.1,	 2.5,	 and	 3.2),	 (3.95,	 2.62,	 and	 3.21)	 and	 (3.9,	 2.65,	 and	
3.31),	respectively.	As	can	also	be	seen	from	these	results,	good	
values	 of	 the	 resolution	 factor	 were	 obtained	 for	 all	 these	
variations,	 indicating	 good	 robustness	 of	 the	 proposed	 LC	
method.	No	interference	was	observed	from	the	peak	of	CGN	in	
all	the	previously	mentioned	conditions.	
	
3.3.6.	Limit	of	detection	and	limit	of	quantification	
	
Limit	 of	 detection	 (LOD)	 which	 represents	 the	
concentration	 of	 analyte	 at	 S/N	 ratio	 of	 3	 and	 limit	 of	
quantification	 (LOQ)	 at	 which	 S/N	 is	 10	 were	 determined	
experimentally	for	the	proposed	methods	and	results	are	given	
in	Tables	4	and	5.	
	
3.3.7.	Statistical	analysis	
	
Statistical	analysis	of	the	results	obtained	by	the	proposed	
methods	and	the	reference	methods	for	each	drug	were	carried	
out	 by	 “SPSS	 statistical	 package	 version	 11”.	 The	 significant	
difference	 between	 the	 reference	methods	 and	 the	 described	
methods	was	tested	by	one	way	ANOVA	(F‐test)	at	p	=	0.05	as	
shown	in	Tables	6	and	7.	The	test	ascertained	that	there	was	no	
significant	difference	among	the	methods.	
	
4.	Conclusion	
	
The	proposed	LC	method	has	the	advantages	of	simplicity,	
precision,	 accuracy	 and	 convenience	 for	 the	 separation	 and	
quantization	of	 STG,	 VDG	or	 SXG	 in	 combination	with	MET	 in	
the	 presence	 of	 CGN.	 The	 method	 can	 be	 applied	 for	 the	
determination	 of	 the	 cited	 drugs	 in	 pharmaceutical	 dosage	
forms.	The	method	was	validated	showing	satisfactory	data	for	
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all	 the	 method	 validation	 parameters	 tested.	 The	 developed	
method	 can	 be	 conveniently	 used	 by	 quality	 control	
laboratories.	
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